Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
07 2019
Historique:
received: 26 09 2018
accepted: 04 02 2019
pubmed: 15 2 2019
medline: 2 7 2020
entrez: 15 2 2019
Statut: ppublish

Résumé

We analyzed 186 patients with lymphoma who underwent allogeneic stem cell transplantation (ASCT) with fludarabine-melphalan (FM) conditioning and different types of donors (25 haploidentical [HD], 98 matched unrelated [MUD], and 63 matched related [MRD]) at our institution between September 2009 and January 2018. Patients received fludarabine 160 mg/m

Identifiants

pubmed: 30763728
pii: S1083-8791(19)30097-7
doi: 10.1016/j.bbmt.2019.02.002
pmc: PMC8265611
mid: NIHMS1585860
pii:
doi:

Substances chimiques

Vidarabine FA2DM6879K
fludarabine P2K93U8740
Melphalan Q41OR9510P

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1340-1346

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Références

Biol Blood Marrow Transplant. 2018 Jun;24(6):1237-1242
pubmed: 29378303
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Bone Marrow Transplant. 2018 Sep;53(9):1139-1148
pubmed: 29540849
Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62
pubmed: 17382251
Blood. 2001 Feb 1;97(3):631-7
pubmed: 11157478
Bone Marrow Transplant. 2003 Apr;31(8):667-78
pubmed: 12692607
Blood. 2016 Feb 18;127(7):938-47
pubmed: 26670632
Biol Blood Marrow Transplant. 2016 Nov;22(11):2047-2055
pubmed: 27522040
Bone Marrow Transplant. 2017 Jun;52(6):811-817
pubmed: 28287639
Biol Blood Marrow Transplant. 2013 Mar;19(3):344-56
pubmed: 22922522
Biol Blood Marrow Transplant. 2016 Mar;22(3):493-8
pubmed: 26497906
J Hematol Oncol. 2017 Jun 12;10(1):117
pubmed: 28606176
J Clin Oncol. 2017 Oct 20;35(30):3425-3432
pubmed: 28846465
Nat Rev Clin Oncol. 2018 Aug;15(8):510-527
pubmed: 29777163
Cancer. 2018 Apr 15;124(8):1733-1742
pubmed: 29424927
J Clin Oncol. 2016 Sep 10;34(26):3141-9
pubmed: 27269951
Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):655-63
pubmed: 26428486
Cancer. 2016 Nov 15;122(21):3316-3326
pubmed: 27404668
J Clin Oncol. 2013 Apr 1;31(10):1310-6
pubmed: 23423745
Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-1551
pubmed: 27131863
Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
pubmed: 18489989
Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87
pubmed: 18940683
Bone Marrow Transplant. 2016 Jul;51(7):949-54
pubmed: 26999464
Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8
pubmed: 23872222

Auteurs

Neeraj Y Saini (NY)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Rima M Saliba (RM)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Gabriela Rondon (G)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Farzaneh Maadani (F)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Uday Popat (U)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Chitra M Hosing (CM)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Betul Oran (B)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Qaiser Bashir (Q)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Amanda Olson (A)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Yago Nieto (Y)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Amin Alousi (A)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Partow Kebriaei (P)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Samer Srour (S)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Rohtesh Mehta (R)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Paolo Anderlini (P)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Elizabeth J Shpall (EJ)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Muzaffar H Qazilbash (MH)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Issa F Khouri (IF)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Luis Fayad (L)

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Hun Lee (H)

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Nathan Fowler (N)

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Simrit Parmar (S)

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Jason Westin (J)

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Fredrick Hagemeister (F)

Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Richard E Champlin (RE)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Stefan O Ciurea (SO)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: sciurea@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH